PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12N 5/00 | A1

(11) International Publication Number: WO 96/33264

(43) International Publication Date: 24 October 1996 (24.10.96)

(21) International Application Number: PCT/US96/05066

(22) International Filing Date: 12 April 1996 (12.04.96)

(30) Priority Data:
08/425,868 20 April 1995 (20.04.95) US

(71) Applicant: UNIVERSITY OF SOUTH FLORIDA [US/US]; FAO 126, 4202 East Fowler Avenue, Tampa, FL 33620 (US).

(72) Inventors: HELLER, Richard; 1102 Pine Ridge Circle West, Brandon, FL 33511 (US). CAMERON, Don, F.; 18206 Clear Lake Drive, Lutz, FL 33549 (US). SANBERG, Paul, R.; 11751 Pilot Country Drive, Spring Hill, FL 34610 (US). JAROSZESKI, Mark, J.; Apartment 307, 15501 Bruce B. Downs Boulevard, Tampa, FL 33647 (US).

(74) Agent: KOHN, Kenneth, I.; Kohn & Associates, Suite 410, 30500 Northwestern Highway, Farmington Hills, MI 48334 (US).

(81) Designated States: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, LK, LR, LS, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, SG, SK, TR, TT, UA, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: PURIFIED AND ISOLATED SERTOLI CELL AGGREGATE

(57) Abstract

A purified and isolated Sertoli cell aggregate characterized by being a) capable of survival in situ after transplantation; b) able to provide immunoprotection for co-transplanted cells; and c) able to provide a mechanism for prolonged viability and functionality of the transplanted cells.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia
AT	Austria
AU	Australia
BB	Barbados
BE	Belgium
BF	Burkina Faso
BG	Bulgaria
BJ	Benin
BR	Brazil
BY	Belarus
CA	Canada
CF	Central African Republic
CG	Congo
CH	Switzerland
CI	Côte d'Ivoire
CM	Cameroon
CN	China
CS	Czechoslovakia
CZ	Czech Republic
DE	Germany
DK	Denmark
EE	Estonia
ES	Spain
FI	Finland
FR	France
GA	Gabon
GB	United Kingdom
GE	Georgia
GN	Guinea
GR	Greece
HU	Hungary
IE	Ireland
IT	Italy
JP	Japan
KE	Kenya
KG	Kyrgystan
KP	Democratic People's Republic of Korea
KR	Republic of Korea
KZ	Kazakhstan
LI	Liechtenstein
LK	Sri Lanka
LR	Liberia
LT	Lithuania
LU	Luxembourg
LV	Latvia
MC	Monaco
MD	Republic of Moldova
MG	Madagascar
ML	Mali
MN	Mongolia
MR	Mauritania
MW	Malawi
MX	Mexico
NE	Niger
NL	Netherlands
NO	Norway
NZ	New Zealand
PL	Poland
PT	Portugal
RO	Romania
RU	Russian Federation
SD	Sudan
SE	Sweden
SG	Singapore
SI	Slovenia
SK	Slovakia
SN	Senegal
SZ	Swaziland
TD	Chad
TG	Togo
TJ	Tajikistan
TT	Trinidad and Tobago
UA	Ukraine
UG	Uganda
US	United States of America
UZ	Uzbekistan
VN	Viet Nam

PURIFIED AND ISOLATED SERTOLI CELL AGGREGATE

TECHNICAL FIELD

The present invention relates to the field of fused or aggregated cells having desired functional and immunological capabilities and the use of such cells.

BACKGROUND ART

Advances in cell fusion technology have allowed for cell fusion to become an important tool in biotechnology. For example, one key procedure in genetic engineering is the introduction of exogenous genetic material into a desired host cell. The insertion can be accomplished by various means and techniques. Cell fusion is also important in the production of monoclonal antibodies. Specifically, the monoclonal antibodies can be produced by the fusion of antibody producing cells with continuously dividing cancer cells. (Galfre, G. et al., 1977; Lo, M.M.S. et al., 1984). Conventional cell fusion techniques are summarized in U.S. Patent 4,822,470 to Chang, issued April 18, 1989. Methods of using an apparatus for cell poration and cell fusion are

disclosed in the Chang patent as well as the U.S. Patent 4,955,378 to Grasso, issued September 11, 1990, although these disclosures are not exhaustive of the state of the art.

From the above mentioned prior art, it can be concluded that it is no longer a novel concept to generally combine two cells having different functions resulting in a fused cell or hybrid capable of the combined functions of the two precursor cells.

The present invention relates to utilizing the aforementioned technology with regard to problems related to, for example, insulin dependent diabetes. A major problem is immunologic rejection of transplanted cells. It has recently been shown that if you co-transplant with Sertoli cells, the graft would avoid immune rejection and survive indefinitely. Insulin dependent diabetes is a major health problem throughout the world for which a cure is not yet available. A desirable approach to alleviating the complications of this disease is to provide the patient with an endogenous insulin. This can be accomplished through the transplantation of insulin secreting cells (islet cells).

There are several major difficulties in cell transplantation in general and in the transplantation of islet cells in specific.

Major difficulties with regard to islet cell transplantation are the lack of allografts and the inevitable rejection of allograft substitutes (xenografts).

In order to avoid transplantation rejection, the state of the art methodology is to use systemically delivered immunosuppressant therapy. However, this renders patients susceptible to many infectious agents, the infectious agents often times being more life threatening than the disease itself. Accordingly, it is desirable to alleviate this major problem by creating local immunosuppression at the transplantation site, thereby obviating the need for systemic immunosuppressant therapy.

Recently, it has been demonstrated that pancreatic islet cells can be successfully transplanted at sites where they were typically rejected if grafted with Sertoli cells isolated from the testis. Islet cells of the Sertoli-islet grafts also maintained their ability to secrete insulin in response to the usual stimuli. Once diabetic rats became normoglycemic within twenty-four hours of transplantation (Selawry and Cameron, 1993).

Although the aforementioned cell co-transplantation protocol was successful, the procedure is limited by the difficult nature of

primary cell isolation between both Sertoli cells and islet cells. In addition, there are related complications in maintaining a close association of the two cell types.

The unique mechanism of graft survival appears primarily dependent upon the secretion of immunosuppressant factors by the Sertoli cells at the site of transplantation. Therefore, separation of the two cell types following transplantation would result in the rejection of the islet cells and return the animal to the diabetic state.

In view of the above, it is desirable to produce cell aggregates for use in the treatment of various diseases wherein the aggregates function both as a secretory cell to perform a specific desired function, such as either a curative function, supplemental function, or inhibitory function, in conjunction with the ability of performing an immuno-protective function of the same cells. More specifically, it would be desirable to produce transplantable insulin producing islet cell aggregates to be used in the treatment of insulin dependent diabetes which also effectively avoid immune surveillance in a manner similar to the Sertoli cell-islet cell co-transplants described above.

SUMMARY OF THE INVENTION

In accordance with the present invention, there is provided a purified isolated Sertoli cell aggregate characterized by being

a) capable of survival in situ after transplantation;

b) able to provide immunoprotection for co-transplanted cells; and

c) able to provide a mechanism for prolonged viability and functionality of the transplanted cells.

BRIEF DESCRIPTION OF THE FIGURES

Other advantages of the present invention will be readily appreciated as the same becomes better understood by reference to the following detailed description when considered in connection with the accompanying drawings wherein:

FIGURE 1 is a fluorescent light photomicrograph of cells following electrofusion, unfused cells are stained red and green and fused hybrid cells appear yellow;

FIGURE 2 is a light photomicrograph of hybrid cells in vitro derived from mouse TM4 cells and rat Sertoli cells; and

FIGURE 3 is a light photomicrograph which illustrates the subcapsular region of a grafted rat kidney, normal kidney parenchyma (K) is observed along with two normal appearing pancreatic islets (IL), upper inset: at higher magnification, the distinctive structure of Sertoli cells with characteristic irregular nuclear profiles and nucleoli (arrows) and intral-islet B cells (B) can be seen to better advantage, lower inset: at higher magnification/resolution, this electron micrograph illustrates a B cell (B) with characteristic insulin secretory granules.

DETAILED DESCRIPTION OF THE INVENTION

In accordance with the present invention, a purified and isolated cell aggregate is provided. The cell aggregate is characterized by being capable of survival in situ after transplantation able to maintain a secretory function in response to in situ stimuli, and effectively avoiding in situ immune surveillance.

More specifically, the purified isolated cell aggregate is produced either as a hybrid and/or aggregate of separate cells in culture. As described above with regard to the prior art, both transplantation of Sertoli cells and secretory cells have resulted an effective treatment of insulin dependent diabetes. The present invention utilizes what is termed a "cell aggregate" of the Sertoli cells and secretory cells to produce an effective treatment for certain diseases such as insulin dependent diabetes or Parkinson's disease while also alleviating the problems caused by separation of the two cell types following transplantation. That is, there is a greater number of Sertoli cells in the hybrid than the number of secretory cells.

Aggregation of the cells can be accomplished by means well known in the art. For example, cell fusion can be accomplished pursuant to the methods disclosed in the U.S. Patent 4,822,470 to Chang, issued April 18, 1989, those methods being incorporated herein by reference. Likewise, the methods disclosed in the U.S. Patent 4,441,972 to Pohl, issued April 10, 1984, can also be used. Both prior art patents disclose methods for fusing neutral polarizable biological bodies and sorting the bodies by

exposing them to a non-uniform electric field. Both reference disclose the effective use of such methods, such as in producing antibody producing hybrids and the combination of antibody producing cells and cancer cells.

By being capable of survival in situ after transplantation, the cell aggregates must thrive and also avoid in situ immune surveillance. Sertoli cells are nutritive supplying cells. (Bardin et al., 1988) Accordingly, the Sertoli cells, as part of the cell aggregate/hybrid, provide a nutritive effect for the aggregate/hybrid cells thereby increasing the survival of their survival. Survival after transplantation requires mechanisms for effectively avoiding in situ immuno-surveillance. Following transplantation, Sertoli cells have been shown to produce such an effect in situ, as demonstrated in the references set forth above. Hence, a combination of Sertoli cells with other cell types, such as islet cells, as a cell aggregate provides a transplantable three-dimensional aggregate capable of maintaining its functional characteristics such as secreting insulin and effectively avoiding immunological rejection.

In a preferred embodiment of the present invention produced in accordance with the

present invention, a purified and isolated islet cell aggregate is provided. The islet cell aggregate is characterized by being capable of survival in situ after transplantation, able to produce insulin in situ, and the production of insulin being controllable by in situ demand for insulin.

More specifically, the purified isolated islet cell aggregate is produced either as a hybrid or aggregate of separate cells in culture. As described above with regard to the prior art, both transplantation of Sertoli cells and islet cells have resulted an effective treatment of insulin dependent diabetes. Critical to the effectiveness and utility of the cell aggregates is the further combination of functions of the cell aggregates being able to maintain relevant functionality of the transplanted cell. For example, for diabetes the cell aggregates must be able to produce insulin in situ while the production of insulin remains controllable by in situ demand for insulin. That is, the cell aggregates must be glucose sensitive and react accordingly to the production or non-production of insulin. That is, the cell aggregates must be glucose sensitive and react accordingly to the production or non-production of insulin. Hence, the present invention

provides transplantable cell aggregates able to produce insulin to produce a curative effect wherein the cells are regulatable in situ to provide an appropriate curative and maintenance effect.

In view of the above, the present invention more broadly provides a cell aggregate which can be, for example, a hybrid resulting from the combination of an immuno-protective cell (Sertoli cell) and a secretory cell, such as an insulin producing cell, other secretory cells which can produce hormone, or a regulatory compound. Such aggregates, as demonstrated by the experimental section below, are capable of both in situ survival after transplantation and maintaining secretory function in response to in situ stimuli. By effectively avoiding in situ surveillance, these cells can be utilized for various curative, diagnostic, and maintenance providing functions.

Examples of secretory cells useful with regard to the present invention are chromaffin cells (Parkinson's Disease). It should be understood that the secretory function can include both naturally occurring products as well as engineered products.

Transplantation protocol can follow the procedure as described in Pakzaban et al., (1993)

which can include infusing the cell aggregate into a target site.

As stated above, the present invention provides significant utility as a therapeutic. The present invention can also be utilized in vitro as a cell culture of extended life secretory cells which can be used as a test system for various therapeutics. For example, a preferred embodiment of the present invention which provides the islet cell aggregate, various diabetic treatments can be tested solely with regard to their effect on islet cells by use of the present system. This method would include the steps of providing a cell culture, adding a drug to be tested, and then monitoring the response of the cells. This type of test system is a well known method in the art. Such a system would utilize the nutritive effects of the Sertoli cells to decrease the nutrient requirements of the ongoing cell culture as well as to provide a biologically nourishing environment for the test cells.

The following experimental section illustrates the method of making and utilizing the present invention. Also, the following experiments clearly demonstrate the utility of the present invention and an in vitro and in vivo system.

EXPERIMENTAL SECTION

Cell-Cell Electrofusion:

A pulse generator (Model T800, BTX, San Diego, California can be used to deliver the electrical energy required to induce fusion. Pulses can be monitored using a digital storage oscilloscope with a custom written software package to analyze waveforms captured by the oscilloscope. The required to induce cell-cell contact can be a chamber developed in our laboratory (Jaroszeski et al., "Mechanically facilitated cell-cell electrofusion" Biophys. J. 67:1574-1581). Electrofusion of the different cell pairings can be achieved in the chamber using our standard protocol. Briefly, the chamber consists of two electrodes contained in a plexiglass housing to support and align the electrodes and to allow the distance between the electrodes to be precisely calibrated. One cell type from each of the cell pairings can be deposited, using vacuum, onto a polycarbonate track etch membrane (Poretics Corporation, Livermore, California) and placed over the face of the anode. Similarly, the other cell type can be deposited onto the face of the cathode. The

layers of cells on each membrane can be contacted with each other by moving the electrode faces to a precisely calibrated distance at which time fusogenic direct current pulses will be administered. Pulse parameters are identified to provide maximum yields of hybrid cells.

Detection and Quantitation of Fusion Products:

Detection and quantitation of fusion produces can be achieved using a method developed by our research group and described in the publication (Jaroszeski et al., 1993). The method utilizes flow cytometry in conjunction with two different vital fluorescent dyes. One fusion partner will be stained with 5-chloromethylfluorescein diacetate (CMFDA) and the other will be stained with 5-(and 6-)-4 chloromethylbenzoyl amino) tetramethylrhodamine (CMTMR). Cell staining is conducted prior to electrofusion. After fusion, cells that are composed of at least one fusion partner of each type will exhibit the fluorescence of both dyes (dual fluorescence). Detection and quantitation of fusion products can be conducted using a Becton Dickinson FACStar Plus flow cytometer with an 80 mW argon laser tuned to a wavelength of 488 nm. The FL1 (green) cytometer channel can be

used to detect CMFDA emission; CMTMR emission is detected in the FL1 (red) channel. Hybrid cells can be sorted based on FL1 vs. FL2 dot plots. Cells that exhibit dual fluorescence can be sorted and collected for subsequent growth and characterization.

The above data demonstrates the methods of making, utilizing, and utility of the present invention in in vivo and in vitro systems.

Throughout this application various publications are referenced by citation or number. Full citations for the publications referenced by number are listed below. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains.

The invention has been described in an illustrative manner, and it is to be understood that the terminology which has been used is intended to be in the nature of words of description rather than of limitation.

Obviously many modifications and variations of the present invention are possible in light of the above teachings. It is, therefore, to be understood that within the scope

of the appended claims the invention may be practiced otherwise than as specifically described.

REFERENCES CITED

Bardin et al., The Sertoli Cell. In: The Physiology of Reproduction, Knobil, E. and J. Neil (eds). Raven Press, Ltd., New York, pp. 933-947.

Galfre, G., Nature 266:550-552 (1977).

Jaroszeski et al., "Mechanically facilitated cell-cell electrofusion" Biophys. J. 67:1574-1581.

Jaroszeski et al., "Detection and Quantitation of cell-cell electrofusion products by flow cytometry" Anal. Biochem. 21 6:271-275 (1993).

Lo, M.M.S. et al., Nature 310:794-796 (1984).

Pakzaban et al., "Increased proportion of Ache-rich zones and improved morphological integration in host striatum of fetal..." Exp. Brain Res., 97:13-22 (1993).

Selawry and Cameron, "Sertoli cell-enriched fractions in successful islet cell transplantation" Cell Transplan. 2:123-129 (1993).

What is claimed is:

1. A purified and isolated Sertoli cell aggregate characterized by being

a) capable of survival in situ after transplantation;

b) able to provide immunoprotection for co-transplanted cells; and

c) able to provide a mechanism for prolonged viability and functionality of the transplanted cells.

2. A cell aggregate as set forth in claim 1 including cellular means for effectively avoiding in situ immune surveillance.

3. A cell aggregate as set forth in claim 2 wherein said cellular means includes Sertoli cells as a transplantable three-dimensional aggregate capable of effectively avoiding immunological rejection.

4. A cell aggregate as set forth in claim 1 wherein said aggregates are hybrid cells consisting of fused Sertoli cells.

5. A cell aggregate as set forth in claim 4 wherein said hybrid cells are formed by electrofusion.

6. A cell aggregate as set forth in claim 1 wherein said co-transplanted cells are islet cells.

7. A purified and isolated cell aggregate comprising an aggregate of a secretory cell and an immunoprotective cell; said aggregate being characterized by:

a) being capable of survival in situ after transplantation;

b) maintaining a secretory function in response to in situ stimuli; and

c) effectively avoiding in situ immune surveillance.

8. A cell aggregate as set forth in claim 7 wherein said cell aggregates are hybrid cells consisting of fused secretory cells and islet cells.

Fig - 1



Fig - 2



Fig - 3

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US96/05066

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :C12N 5/00
US CL :435/240.1, 240.2, 240.26

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/240.1, 240.2, 240.26

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, CA, EMBASE, MEDLINE, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	JAROSZESKI, M.J. et al. Detection and Quantitation of Cell-Cell Electrofusion Products by Flow Cytometry. Anal. Biochem. 1994, Vol. 216, pages 271-275, see entire article.	1-8
Y	SELAWRY, H.P. et al. Sertoli Cell-Enriched Fractions in Successful Islet Cell Transplantation. Cell Transplan. 1993, Vol. 2, pages 123-129, especially pages 123 and 124.	1-8
Y	US 4,195,125 A (WACKER) 25 March 1980, see entire reference.	1-8
Y	US 4,455,296 (HANSEN et al.) 19 June 1984, see entire reference.	1-8

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
08 JULY 1996	24 JUL 1996
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer Kristin Larson Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)*